AutoGenomics begins new Hepatitis C virus genotyping test
The World Health Organization (WHO) estimates that 150 million people are living with chronic HCV infections. Within the U.S., HCV infection is the single most common bloodborne infection, afflicting approximately 3.2 million people.
The new therapy is an assay that is engineered to detect six HCV genotypes and two HCV subtypes with just one test. The test implements the company’s proprietary multiplexing microarray technology. As of today, the test is only available for research purposes and not diagnostic methods. The company plans to seek Food and Drug Administration approval for the test.
“We are making this assay available on our INFINITI Plus and INFINITI High Throughput System to reach low, medium and high volume testing sites” Fareed Kureshy, President and Chief Executive Officer of AutoGenomics, said.
AutoGenomics, currently based in Vista, California, is a privately held company that created the original automated, microarray based multiplexing diagnostic platform. This platform can assess disease signatures using novel proteomic and genomic markers.